Obesity, the future eldorado of pharmacy


Two laboratories should share most of the cake, the Danish NovoNordisk and the American Lilly, with their therapeutic hormones. Vadym – stock.adobe.com

This market could pass 50 billion dollars in revenue by 2030.

It is a scourge that is spreading across the world, now affecting Europe and Asia, and no longer just the United States. Obesity could generate $54 billion in revenue by 2030, according to Morgan Stanley analysts. They see it as the next pool of blockbusters (drugs with more than 1 billion in sales), comparable to the rise of the hypertension market in the 1990s, which peaked at 30 billion dollars.

The potential of this market can first be explained by the meteoric rise in obesity. 650 million people are obese on the planet, 1.9 billion overweight. France has 8.5 million obese people (17% of the adult population), an increase of 13% in ten years. On the other hand, it is a pathology very little supported. Patients are still largely reluctant to consult a doctor, and doctors are poorly trained in this disease and in therapeutic solutions. But the environment…

This article is for subscribers only. You have 75% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

Already subscribed? Login



Source link -93